Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-609A in Advanced Undifferentiated Pleomorphic Sarcoma
NCT05193214Phase 2Unknown
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 609A in undifferentiated pleomorphic sarcoma (UPS), sponsored by 3S Guojian Pharmaceutical. Primary endpoint: Objective Response Rate at 18 months. Status: unknown.
02
Drugs
609A
03
Conditions
undifferentiated pleomorphic sarcoma (UPS)
Beyond the preview
Go deeper on NCT05193214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05193214.